Rasgap derived peptide for selectively killing cancer cells

Details Rasgap derived peptide for selectively killing cancer cells Rasgap derived peptide for selectively killing cancer cells

C - Chemistry, Metallurgy

07

K

C07K 14/47 (2006.01) A61K 38/17 (2006.01) A61K 47/42 (2006.01) A61P 35/00 (2006.01) C12N 15/12 (2006.01)

Patent

CA 2530613

The present invention relates to a peptide consisting in the N2 sequence of the RasGAP protein, a fragment thereof, or a variant thereof which enhances the ability of a drug to selectively kill cells. Furthermore, it relates to a pharmaceutical composition comprising as an active substance a pharmaceutically effective amount of said peptide.

L'invention concerne un peptide qui comprend la séquence N2 de la protéine RasGAP, un de ses fragments ou variantes qui augmente la capacité d'un médicament de tuer sélectivement des cellules. En outre, l'invention concerne une composition pharmaceutique qui contient comme substance active une quantité pharmaceutiquement efficace de ce peptide.

Affiliated with

Also associated with

Rating

Rasgap derived peptide for selectively killing cancer cells does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Rasgap derived peptide for selectively killing cancer cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Rasgap derived peptide for selectively killing cancer cells will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1465286